Client · LDA

ASSOCIATION FOR MOLECULAR PATHOLOGY

5 filings 8 bills mentioned 1 registrants 5 quarters ~$352,500 reported

Client ID

203254

Bills lobbied on

Bills referenced in this client's quarterly filings, ranked by filing count.

S 1546

Patent Eligibility Restoration Act of 2025

CPT

4

HR 3152

Patent Eligibility Restoration Act of 2025

CPT

4

HR 5269

RESULTS Act

MMM

2

S 2761

RESULTS Act

MMM

2

HR 1463

To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.

MED

2

SJRES 82

A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Office of the Secretary of the Department of Health and Human Services relating to "Policy on Adhering to the Text of the Administrative Procedure Act".

MED

2

HR 2471

Right Drug Dose Now Act of 2025

HCR

1

HR 4121

Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

BUD

1

Registrants

Lobbying firms that filed on behalf of this client.

IPOLICY SOLUTIONS 5

Source: Senate LDA quarterly filings (LD-2). Bill mentions extracted from free-text "specific issues" descriptions.